Citizens JMP lowered the firm’s price target on Prelude Therapeutics (PRLD) to $3 from $4 and keeps an Outperform rating on the shares. With initial PRT3789 monotherapy data validating the SMARCA2 target, the firm says PRT7732 has a path forward as a combination agent, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRLD:
- Prelude Therapeutics Reports Q2 2025 Financial Results
- Prelude Therapeutics Pauses Intravenous SMARCA2 Degrader Development
- Prelude Therapeutics reports Q2 EPS (41c), consensus (43c)
- PRLD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Prelude Therapeutics Advances Cancer Treatment with PRT7732 Study